(AVDL) – Company Press Releases
-
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
-
Avadel Pharmaceuticals Issues Statement On Patent Litigation
-
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4
-
Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Satellos Announces Management Team Update
-
Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights
-
Illuminate Hypersomnia Initiative Shines Light on What It's Like to Live with Idiopathic Hypersomnia
-
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 8
-
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023
-
Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
-
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
-
Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation’s 2023 Young Investigators Research Forum
-
Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy
-
Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
-
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023
-
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
-
Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares
-
Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares
-
Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million
-
Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension
-
Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
Back to AVDL Stock Lookup
